Bioelectrochemical biosensors for water quality assessment and wastewater monitoring

Bioelectrochemical biosensors offer a promising approach for real-time monitoring of industrial bioprocesses. Many bioelectrochemical biosensors do not require additional labelling reagents for target molecules. This simplifies the monitoring process, reduces costs, and minimizes potential contamination risks. Advancements in materials science and microfabrication technologies are paving the way for smaller, more portable bioelectrochemical biosensors. This opens doors for integration into existing bioprocessing equipment and facilitates on-site, real-time monitoring capabilities. Biosensors can be designed to detect specific heavy metals such as lead, mercury, or chromium in wastewater. Early detection allows for the implementation of appropriate removal techniques before they reach the environment. Despite these challenges, bioelectrochemical biosensors offer a significant leap forward in wastewater monitoring. As research continues to improve their robustness, selectivity, and cost-effectiveness, they have the potential to become a cornerstone of efficient and sustainable wastewater treatment practices.

Ultrasensitive Electrochemical Immunosensor for Multiplex Sandwich Bioassaying Based on the Functional Antibodies

In vitro diagnostics (IVDs) based on electrochemical immunosensors are crucial for disease screening, diagnosis, prognosis, and treatment monitoring. However, label-free electrochemical immunosensors commonly suffer from poor specificity, leading to false positives. To address this issue, we propose a highly sensitive and precise electrochemical immunosensor for protein marker detection. This approach involves directly labeling the detection antibodies (Ab2) with thionine (Thi). The Ab2 labeled by Thi exhibits a distinct redox peak upon targeted voltage stimulation, enabling accurate quantification of protein biomarkers. Thi-modified antibodies provide significant advantages over traditional antibody modification methods, such as enhanced detection sensitivity, improved accuracy, and specificity in protein marker identification. The method is straightforward and efficient, ensuring specific analyte detection while minimizing interference from other substances in the sample. Additionally, a multielectrode detection method was employed, achieving remarkably low limits of detection (LoDs) for tumor necrosis factor-alpha (TNF-alpha), cardiac troponin I (cTnI), and interleukin-6 (IL-6), with LoDs of 9.38 fg/mL, 1.70 fg/mL, and 8.14 fg/mL, respectively. The proposed electrochemical immunosensor also exhibited high selectivity and repeatability, with relative standard deviations (RSD) of 6.39% for TNF-alpha, 2.42% for cTnI, and 2.72% for IL-6 (n = 5). Moreover, it demonstrated high sensitivity and was evaluated for serum detection using the standard addition method. The results highlight the great potential of the proposed electrochemical immunosensor for clinical applications, offering a novel approach for future utilization in clinical settings.

Protein Corona Sensor Array Nanosystem for Detection of Coronary Artery Disease

Coronary artery disease (CAD) is the most common type of heart disease and represents the leading cause of death in both men and women worldwide. Early detection of CAD is crucial for decreasing mortality, prolonging survival, and improving patient quality of life. Herein, a non-invasive is described, nanoparticle-based diagnostic technology which takes advantages of proteomic changes in the nano-bio interface for CAD detection. Nanoparticles (NPs) exposed to biological fluids adsorb on their surface a layer of proteins, the "protein corona" (PC). Pathological changes that alter the plasma proteome can directly result in changes in the PC. By forming disease-specific PCs on six NPs with varying physicochemical properties, a PC-based sensor array is developed for detection of CAD using specific PC pattern recognition. While the PC of a single NP may not provide the required specificity, it is reasoned that multivariate PCs across NPs with different surface chemistries, can provide the desirable information to selectively discriminate the condition under investigation. The results suggest that such an approach can detect CAD with an accuracy of 92.84%, a sensitivity of 87.5%, and a specificity of 82.5%. These new findings demonstrate the potential of PC-based sensor array detection systems for clinical use.

Simple and fast colorimetric and electrochemical methods for the ultrasensitive detection of glucose

Developing ultrasensitive and user-friendly methods for the detection glucose has attracted more and more attention. By virtue of high selectivity and sensitivity, enzyme-based glucose sensor plays a key role in point-of-care sensing technology for detecting glucose concentration. In this study, Amplex Red (AR), as both indicator and mediator, was investigated to detect glucose in presence of glucose oxidase (GOx) enzymes using colorimetric and electrochemical methods. Without using any advanced techniques and sophisticated nanomaterials, 1 μM glucose can be easily detected through simply detecting the solution color with a visual colorimetric method. On the other hand, the electrochemical method can provide much higher sensitivity for the detection of glucose, which achieves a linear range spanning from 20 nM to 3.56 μM with a limit of 7.3 nM (signal-to-noise ratio SNR = 3). It is also found that the presence of other sugars such as fructose, lactose, and maltose have very limited interference effects on the detection of glucose. More importantly, a bare GC electrode was used in all these electrochemical measurements without any electrode surface modification, guaranteeing a simple and fast operation. The analytical platforms for the detection of glucose presented here not only provide simple, fast, and ultrasensitive methods, but also have the potential to advance the sensing technology in the application of other health diagnostic research areas. Amplex Red (AR) was reported as both an indicator and mediator for the sensitive and specific determination of glucose using the colorimetric and electrochemical methods. The detection limit was 1 μM glucose by the visual colorimetric methods. A bare glassy carbon electrode without any functional modification was employed for the detection as low as 20 nM glucose with LOD of 7.3 nm (SNR = 3) in the electrochemical method.

Layered Double Hydroxide-Modified Organic Electrochemical Transistor for Glucose and Lactate Biosensing

Biosensors based on Organic Electrochemical Transistors (OECTs) are developed for the selective detection of glucose and lactate. The transistor architecture provides signal amplification (gain) with respect to the simple amperometric response. The biosensors are based on a poly(3,4-ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS) channel and the gate electrode is functionalised with glucose oxidase (GOx) or lactate oxidase (LOx) enzymes, which are immobilised within a Ni/Al Layered Double Hydroxide (LDH) through a one-step electrodeposition procedure. The here-designed OECT architecture allows minimising the required amount of enzyme during electrodeposition. The output signal of the biosensor is the drain current (I_d), which decreases as the analyte concentration increases. In the optimised conditions, the biosensor responds to glucose in the range of 0.1–8.0 mM with a limit of detection (LOD) of 0.02 mM. Two regimes of proportionality are observed. For concentrations lower than 1.0 mM, a linear response is obtained with a mean gain of 360, whereas for concentrations higher than 1.0 mM, I_d is proportional to the logarithm of glucose concentration, with a gain of 220. For lactate detection, the biosensor response is linear in the whole concentration range (0.05–8.0 mM). A LOD of 0.04 mM is reached, with a net gain equal to 400.

Usefulness of estimated average glucose (eAG) in glycemic control and cardiovascular risk reduction

OBJECTIVE

One of the 8 regional health authority (RHA) zones in New Brunswick, Canada has implemented eAG since 2010. We sought to evaluate the clinical outcomes of glycemic control and cardiovascular risk levels before and after the eAG implementation in this zone; and to compare the overall outcomes of this zone with other 7 zones of the province.

METHODS

Data (838,407 HbA1c values and 612,314 LDL-c values) was extracted from all adult diabetic patients in the provincial Diabetes Registry from 2008 to 2014. The Kruskal-Wallis statistic was conducted to compare the medians and inter quartile ranges of HbA1c and LDL-c from different zones. The proportion of patients achieving therapeutic targets, the distribution of HbA1c and LDL-c values pre/post the eAG implementation in RHA Zone 1.1 were assessed by Chi-square analysis.

RESULTS

The proportion of patients achieving targets in Zone 1.1 were at an intermediate level among all 8 zones and the trends of Zone 1.1 were no different than other zones. There were statistically significant differences for Zone 1.1 in the distribution of HbA1c (Z = -12.5190, P < 0.001) and LDL-c (Z = 16.4410, P < 0.001) before and after the eAG reported. The proportion of patients with HbA1c < 53 mmol/mol (7.0%) of the RHA Zone 1.1 was significantly lower after eAG reported (49.85% vs. 47.24%, P < 0.001); while the proportion of patients with LDL-c < 2.6 mmol/L showed statistically significant increase (68.56% vs. 71.90%, P < 0.001).

CONCLUSION

The utilization of eAG has demonstrated no significant impact on glycemic control and cardiovascular risk reduction.

Three-dimensional flower-like Ni–Mn–S on Ti mesh: a monolithic electrochemical platform for detecting glucose

Three-dimensional flower-like Ni–Mn–S on Ti mesh as a monolithic electrochemical platform was constructed and exhibited satisfactory glucose sensing performance.

Fabrication of a promising immobilization platform based on electrochemical synthesis of a conjugated polymer

Since conjugated polymers are an important class of materials with remarkable properties in biosensor applications, in this study, a novel glucose biosensor based on a conjugated polymer was fabricated via the electropolymerization of the monomer 10,13-bis(4-hexylthiophen-2-yl)dipyridol[3,2-a:2',3'-c]phenazine onto a graphite electrode surface. Glucose oxidase (GOx) was used as the model biological recognition element. As a result of the enzymatic reaction between GOx and glucose, the glucose amount was determined by monitoring the change in the oxygen level associated with substrate concentration via the amperometric detection technique. The proposed system possessed superior properties with K_M^app value of 0.262 mM, 2.88 × 10^-3 mM limit of detection and 105.12 μA mM^-1 cm^-2 sensitivity. These results show that conjugated polymer film provides an effective and stable immobilization matrix for the enzyme. Finally, the biosensor was applied successfully to several commercially available beverage samples for glucose determination proving an inexpensive and highly sensitive system applicable for real time analyses.

Cobalt phosphide nanowire array as an effective electrocatalyst for non-enzymatic glucose sensing

A cobalt phosphide nanowire array was grownin situon titanium mesh, exhibiting high catalytic activity towards electrooxidation of glucose, and offering a non-enzymatic electrochemical glucose sensor with remarkable selectivity and long-term stability.

Mineralized growth of Janus membrane with asymmetric wetting property for fast separation of a trace of blood

Janus membranes were fabricated by diffusion-controlled chemical precipitation of needle-like HAP nanocrystals and successfully applied for spontaneous separation of red cells from blood.

From mercury to nanosensors: Past, present and the future perspective of electrochemistry in pharmaceutical and biomedical analysis

Polarography was the first developed automated method of voltage-controlled electrolysis with dropping mercury electrode (DME). Then, hanging mercury drop and static mercury drop electrodes were added as an alternative indicator electrode. In this way, polarography turned formally into voltammetry with mercury electrodes in the electroreduction way. Solid electrodes such as noble metal and carbon based electrodes can be used for the investigation of the compounds for both oxidation and reduction directions, which is called voltammetry. The voltammetric and polarographic techniques are more sensitive, reproducible, and easily used electroanalytical methods that can be alternative to more frequently used separation and spectrometric methods. Furthermore, in some cases there is a relationship between voltammetry and pharmaceutical samples, and the knowledge of the mechanism of their electrode reactions can give a useful clue in elucidation of the mechanism of their interaction with living cells. The voltammetric and polarographic analysis of drugs in pharmaceutical preparations are by far the most common use of electrochemistry for analytical pharmaceutical problems. Recent trends and challenges in the electrochemical methods for the detection of DNA hybridization and pathogens are available. Low cost, small sample requirement and possibility of miniaturization justifies their increasing development.

Non-enzymatic detection of glucose using poly(azure A)-nickel modified glassy carbon electrode

A simple, sensitive and selective non-enzymatic glucose sensor was constructed in this paper. The poly(azure A)-nickel modified glassy carbon electrode was successfully fabricated by the electropolymerization of azure A and the adsorption of Ni(2+). The Ni modified electrode, which was characterized by scanning electron microscope, cyclic voltammetry, electrochemical impedance spectra and X-ray photoelectron spectroscopy measurements, respectively, displayed well-defined current responses of the Ni(III)/Ni(II) couple and showed a good activity for electrocatalytic oxidation of glucose in alkaline medium. Under the optimized conditions, the developed sensor exhibited a broad linear calibration range of 5 μM-12mM for quantification of glucose and a low detection limit of 0.64μM (3σ). The excellent analytical performance including simple structure, fast response time, good anti-interference ability, satisfying stability and reliable reproducibility were also found from the proposed amperometric sensor. The results were satisfactory for the determination of glucose in human serum samples as comparison to those from a local hospital.

Synthesis of carbon nanosheet from barley and its use as non-enzymatic glucose biosensor

In this work, carbon nanosheet (CNS) based electrode was designed for electrochemical biosensing of glucose. CNS has been obtained by the pyrolysis of barley at 600–750 °C in a muffle furnace; it was then purified and functionalized. The CNS has been characterized by scanning electron microscopy (SEM), X-ray diffraction (XRD) and Raman spectroscopic techniques. The electrochemical activity of CNS-based electrode was investigated by linear sweep voltammetry (LSV) and square wave voltammetry (SWV), for the oxidation of glucose in 0.001 M H₂SO₄ (pH 6.0). The linear range of the sensor was found to be 10⁻⁴–10⁻⁶ M (1–100 µM) within the response time of 4 s. Interestingly, its sensitivity reached as high as ~26.002±0.01 μA/μM cm². Electrochemical experiments revealed that the proposed electrode offered an excellent electrochemical activity towards the oxidation of glucose and could be applied for the construction of non-enzymatic glucose biosensors.

A colloidal suspension of nanostructured poly(N-butyl benzimidazole)-graphene sheets with high oxidase yield for analytical glucose and choline detections

A colloidal suspension of nanostructured poly(N-butyl benzimidazole)-graphene sheets (PBBIns-Gs) was used to modify a gold electrode to form a three-dimensional PBBIns-Gs/Au electrode that was sensitive to hydrogen peroxide (H2O2) in the presence of acetic acid (AcOH). The positively charged nanostructured poly(N-butyl benzimidazole) (PBBIns) separated the graphene sheets (Gs) and kept them suspended in an aqueous solution. Additionally, graphene sheets (Gs) formed "diaphragms" that intercalated Gs, which separated PBBIns to prevent tight packing and enhanced the surface area. The PBBIns-Gs/Au electrode exhibited superior sensitivity toward H2O2 relative to the PBBIns-modified Au (PBBIns/Au) electrode. Furthermore, a high yield of glucose oxidase (GOD) on the PBBIns-Gs of 52.3mg GOD per 1mg PBBIns-Gs was obtained from the electrostatic attraction between the positively charged PBBIns-Gs and negatively charged GOD. The non-destructive immobilization of GOD on the surface of the PBBIns-Gs (GOD-PBBIns-Gs) retained 91.5% and 39.2% of bioactivity, respectively, relative to free GOD for the colloidal suspension of the GOD-PBBIns-Gs and its modified Au (GOD-PBBIns-Gs/Au) electrode. Based on advantages including a negative working potential, high sensitivity toward H2O2, and non-destructive immobilization, the proposed glucose biosensor based on an GOD-PBBIns-Gs/Au electrode exhibited a fast response time (5.6s), broad detection range (10μM to 10mM), high sensitivity (143.5μAmM(-1)cm(-2)) and selectivity, and excellent stability. Finally, a choline biosensor was developed by dipping a PBBIns-Gs/Au electrode into a choline oxidase (ChOx) solution for enzyme loading. The choline biosensor had a linear range of 0.1μM to 0.83mM, sensitivity of 494.9μAmM(-1)cm(-2), and detection limit of 0.02μM. The results of glucose and choline measurement indicate that the PBBIns-Gs/Au electrode provides a useful platform for the development of oxidase-based biosensors.

Biosensors in clinical practice: focus on oncohematology

Biosensors are devices that are capable of detecting specific biological analytes and converting their presence or concentration into some electrical, thermal, optical or other signal that can be easily analysed. The first biosensor was designed by Clark and Lyons in 1962 as a means of measuring glucose. Since then, much progress has been made and the applications of biosensors are today potentially boundless. This review is limited to their clinical applications, particularly in the field of oncohematology. Biosensors have recently been developed in order to improve the diagnosis and treatment of patients affected by hematological malignancies, such as the biosensor for assessing the in vitro pre-treatment efficacy of cytarabine in acute myeloid leukemia, and the fluorescence resonance energy transfer-based biosensor for assessing the efficacy of imatinib in chronic myeloid leukemia. The review also considers the challenges and future perspectives of biosensors in clinical practice.

Determination of sulfite with emphasis on biosensing methods: a review

Sulfite is used as a preservative in a variety of food and pharmaceutical industries to inhibit enzymatic and nonenzymatic browning and in brewing industries as an antibacterial and antioxidizing agent. Convenient and reproducible analytical methods employing sulfite oxidase are an attractive alternative to conventional detection methods. Sulfite biosensors are based on measurement of either O2 or electrons generated from splitting of H2O2 or heat released during oxidation of sulfite by immobilized sulfite oxidase. Sulfite biosensors can be grouped into 12 classes. They work optimally within 2 to 900 s, between pH 6.5 and 9.0, 25 and 40 °C, and in the range from 0 to 50,000 μM, with detection limit between 0.2 and 200 μM. Sulfite biosensors measure sulfite in food, beverages, and water and can be reused 100-300 times over a period of 1-240 days. The review presents the principles, merits, and demerits of various analytical methods for determination of sulfite, with special emphasis on sulfite biosensors.

Compact, power-efficient architectures using microvalves and microsensors, for intrathecal, insulin, and other drug delivery systems

This paper describes a valve-regulated architecture, for intrathecal, insulin and other drug delivery systems, that offers high performance and volume efficiency through the use of micromachined components. Multi-drug protocols can be accommodated by using a valve manifold to modulate and mix drug flows from individual reservoirs. A piezoelectrically-actuated silicon microvalve with embedded pressure sensors is used to regulate dosing by throttling flow from a mechanically-pressurized reservoir. A preliminary prototype system is demonstrated with two reservoirs, pressure sensors, and a control circuit board within a 130cm(3) metal casing. Different control modes of the programmable system have been evaluated to mimic clinical applications. Bolus and continuous flow deliveries have been demonstrated. A wide range of delivery rates can be achieved by adjusting the parameters of the manifold valves or reservoir springs. The capability to compensate for changes in delivery pressure has been experimentally verified. The pressure profiles can also be used to detect catheter occlusions and disconnects. The benefits of this architecture compared with alternative options are reviewed.

Design of a prospective clinical study on the agreement between the Continuous GlucoseMonitor, a novel device for CONTinuous ASSessment of blood GLUcose levels, and the RAPIDLab® 1265 blood gas analyser: The CONTASSGLU study

Background

Although a device is needed to continuously measure blood glucose levels within an intensive care setting, and several large-scale prospective studies have shown that patients might benefit from intensive insulin, potassium, or glucose therapy during intensive care, no devices are currently available to continuously assess blood glucose levels in critically ill patients. We conceived the study described here to evaluate the clinical use of the Continuous Glucose Monitor (CGM) performed via a central vein, and to determine the impact of phenomena, such as drift and shift, on the agreement between the CGM and a RAPIDLab® 1265 blood gas analyser (BGA).

Methods/design

In the CONTinuous ASSessment of blood GLUcose (CONTASSGLU) study, up to 130 patients under intensive care will be fitted with the CGM, an ex vivo device that continuously measures blood glucose and lactate levels. Readings from the device taken 8 h after initial placement and calibration will be compared with values measured by a BGA. For this study, we chose the BGA as it is an established standard point-of-care device, instead of the devices used in certified central laboratories. Nevertheless, we will also independently compare the results from the point-of-care BGA with those determined by a central laboratory-based device. Blood samples will be collected from each patient from the same site in which the CGM will measure blood glucose. Consequently, each participant will serve as their own control, and no randomisation is necessary. The 95% limits of agreement and the corresponding confidence intervals will be calculated and compared with a prespecified clinically acceptable relative difference of 20%.

Discussion

Several attempts have been made to develop a device to continuously measure blood glucose levels within an intensive care setting or to use the devices that were originally designed for diabetes management, as several of these devices are already available. However, none of these devices were successful in intensive care settings. CONTASSGLU may well bridge this gap by confirming the ability of the CGM to continuously measure blood glucose levels in intensive care settings.

Trial registration

ClinicalTrials.gov NCT01580176

Facile one-step microwave-assisted route towards Ni nanospheres/reduced graphene oxide hybrids for non-enzymatic glucose sensing

In this work, a facile one-step microwave-assisted method for deposition of monodisperse Ni nanospheres on reduced graphene oxide (rGO) sheets to form Ni-rGO nanohybrids is discussed. In the presence of hydrazine monohydrate, Ni nanospheres are grown onto rGO sheets using nickel precursor and GO as starting materials in ethylene glycol (EG) solution under a low level of microwave irradiation (300 W) for 20 min, during which GO is also reduced to rGO. The as-prepared nanohybrids exhibit well-dispersed Ni nanosphere (about 80 nm in diameter) loadings and effective reduction of graphene oxide. The resulting Ni-rGO nanohybrids-modified glassy carbon electrode (GCE) shows significantly improved electrochemical performance in nonenzymatic amperometric glucose detection. In addition, interference from the oxidation of common interfering species under physiological conditions, such as ascorbic acid (AA) and uric acid (UA), is effectively avoided.

Cancer detection using nanoparticle-based sensors

This tutorial review surveys the latest achievements in the use of nanoparticles to detect cancer biomarkers and cancer cells with a focus on optical and electrochemical techniques. Nanoparticle based cancer diagnostics are becoming an increasingly relevant alternative to traditional techniques. Although some drawbacks exist in relation to the obtained sensitivity the use of nanoparticle-based sensors in biomarker detection or cancer cell detection offers some advantages in comparison to conventional methods. The developed techniques can be interesting and relevant for their use in point-of-care of cancer diagnostics. The methods can be of low cost and in addition easy to be incorporated into user-friendly sensing platforms.